249 related articles for article (PubMed ID: 17062670)
1. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer.
Pootrakul L; Datar RH; Shi SR; Cai J; Hawes D; Groshen SG; Lee AS; Cote RJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5987-93. PubMed ID: 17062670
[TBL] [Abstract][Full Text] [Related]
2. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.
Daneshmand S; Quek ML; Lin E; Lee C; Cote RJ; Hawes D; Cai J; Groshen S; Lieskovsky G; Skinner DG; Lee AS; Pinski J
Hum Pathol; 2007 Oct; 38(10):1547-52. PubMed ID: 17640713
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
4. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.
Zou Z; Zhang W; Young D; Gleave MG; Rennie P; Connell T; Connelly R; Moul J; Srivastava S; Sesterhenn I
Clin Cancer Res; 2002 May; 8(5):1172-7. PubMed ID: 12006534
[TBL] [Abstract][Full Text] [Related]
5. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
6. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.
Tamura K; Furihata M; Chung SY; Uemura M; Yoshioka H; Iiyama T; Ashida S; Nasu Y; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Sci; 2009 May; 100(5):914-9. PubMed ID: 19298603
[TBL] [Abstract][Full Text] [Related]
7. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
8. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
9. Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation.
Belfi CA; Chatterjee S; Gosky DM; Berger SJ; Berger NA
Biochem Biophys Res Commun; 1999 Apr; 257(2):361-8. PubMed ID: 10198218
[TBL] [Abstract][Full Text] [Related]
10. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
11. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
12. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
[TBL] [Abstract][Full Text] [Related]
13. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
14. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development.
Dong D; Ni M; Li J; Xiong S; Ye W; Virrey JJ; Mao C; Ye R; Wang M; Pen L; Dubeau L; Groshen S; Hofman FM; Lee AS
Cancer Res; 2008 Jan; 68(2):498-505. PubMed ID: 18199545
[TBL] [Abstract][Full Text] [Related]
15. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.
Miyake H; Hara I; Gleave ME; Eto H
Prostate; 2004 Dec; 61(4):318-23. PubMed ID: 15389725
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum.
Gonzalez-Gronow M; Cuchacovich M; Llanos C; Urzua C; Gawdi G; Pizzo SV
Cancer Res; 2006 Dec; 66(23):11424-31. PubMed ID: 17145889
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
18. Analysis of cellular sensitization with cisplatin-induced apoptosis by glucose-starved stress in cisplatin-sensitive and -resistant A431 cell line.
Mese H; Sasaki A; Nakayama S; Yokoyama S; Sawada S; Ishikawa T; Matsumura T
Anticancer Res; 2001; 21(2A):1029-33. PubMed ID: 11396136
[TBL] [Abstract][Full Text] [Related]
19. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.
Monet M; Lehen'kyi V; Gackiere F; Firlej V; Vandenberghe M; Roudbaraki M; Gkika D; Pourtier A; Bidaux G; Slomianny C; Delcourt P; Rassendren F; Bergerat JP; Ceraline J; Cabon F; Humez S; Prevarskaya N
Cancer Res; 2010 Feb; 70(3):1225-35. PubMed ID: 20103638
[TBL] [Abstract][Full Text] [Related]
20. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
